Retatrutide in India: Availability, Price and Approval Status

Medically Reviewed: 2 October 2026 • Last Updated: 2 October 2026 • 8 minute read

Where retatrutide stands with regulators, what the trials show, and why no real Indian price exists yet.

Retatrutide in India is not available as an approved medicine. It is an experimental once-weekly injection from Eli Lilly that is still in Phase 3 trials, and it has not been approved for sale anywhere in the world as of October 2026. India’s drug regulator, the CDSCO, has permitted clinical research involving retatrutide, but that is not the same as approval for pharmacies to sell it.

Searches for “retatrutide India” have climbed fast because recent Phase 3 trials reported substantial weight loss, including 28.3% at 80 weeks in TRIUMPH-1. That has also created a grey market, with websites selling “reta” or “retatrutide peptide” at prices that mean nothing. This guide explains the real status, the trial data, and what to do if you need treatment today. Regulatory status checked: October 2026.

What Is Retatrutide?

Retatrutide is an injectable medicine being developed by Eli Lilly for obesity and type 2 diabetes. It is called a triple agonist because it acts on three hormone pathways at once. Semaglutide (Ozempic, Wegovy) works on one, GLP-1. Tirzepatide (Mounjaro) works on two, GLP-1 and GIP. Retatrutide adds a third, glucagon, which is thought to raise the body’s energy use slightly.

GLP-1 and GIP slow digestion and reduce appetite, and the added glucagon activity may explain the larger weight loss seen in trials. It is a once-weekly injection, started low and raised slowly like others in this group.

Is Retatrutide Available in India?

No. The CDSCO, which decides which medicines can be sold in India, has not approved retatrutide. There is no Indian brand, no pharmacy listing and no launch date.

Retatrutide in India exists only inside clinical trials. The CDSCO has permitted clinical trials involving retatrutide, and Indian sites took part in TRANSCEND-T2D-1, the first Phase 3 diabetes trial, alongside sites in the United States and Mexico. People in those trials receive the drug under close medical supervision as part of a study, not as a prescription.

India has separate rules for personal import of certain medicines, but personal import should not be confused with commercial approval. Retatrutide is not approved for routine sale in India, and anyone considering an imported product should speak to a doctor first.

Retatrutide Price in India: Why There Is None

There is no official retatrutide price in India, and there cannot be one until the CDSCO approves it and a company sets a price. Any figure you see on a peptide seller’s site, a marketplace listing or a WhatsApp forward, often labelled “reta price”, is what an unregulated seller has decided to charge for an unverified product.

Until the drug is approved and a company sets a price, treat any quoted price as a sales tactic, not a fact.

Approval Status: FDA and CDSCO

In the United States, retatrutide is still investigational. Eli Lilly announced in July 2026 that it plans to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027, after completing the manufacturing and quality data the agency needs. FDA review usually takes 10 months or more after a filing is accepted, so a decision before 2028 looks unlikely, though nothing is confirmed.

In August 2026, Lilly also opened an early access programme that lets some patients in the United States apply for retatrutide before approval, under medical supervision. This programme is not available in India.

Status as of 2 October 2026. Sources: Eli Lilly announcements and SEC filings, 2026.

What the Phase 3 Trials Show

Several Phase 3 trials have now reported results, including five Phase 3 studies covering obesity and type 2 diabetes. The TRIUMPH trials focus on obesity and the TRANSCEND trials on type 2 diabetes. The amount of weight lost depends heavily on who was studied.

Sources: Eli Lilly topline announcements, December 2025 to September 2026. These are separate trials, not a head-to-head comparison.

For a reader with diabetes, the HbA1c result matters most. In TRANSCEND-T2D-1 it fell by 2.0 percentage points on the 12 mg dose. Our HbA1c chart explains that scale.

Side Effects Seen in Trials

The most common side effects were stomach related: nausea, diarrhoea, vomiting and constipation, usually during dose increases. Dysesthesia, an altered or tingling skin sensation, and urinary tract infections were each reported in around 1 in 10 people on the highest doses in TRIUMPH-1, mostly mild to moderate. In TRIUMPH-1, 11.3% of people on the 12 mg dose stopped treatment because of side effects, compared with 4.9% on placebo.

Rates varied by trial and dose, and the full safety picture is still being built, which is exactly why regulators review a drug before anyone can sell it.

How Retatrutide Compares With Medicines Already in India

India already has approved options. Semaglutide produced about 14.9% average weight loss in its main trial, and tirzepatide about 22.5%. Retatrutide’s 28.3% sits above both, but these come from different trials with different people, doses and durations, so they are not a direct comparison.

If you are weighing today’s options, our guides to semaglutide brands in India, the Wegovy price in India and Mounjaro vs Ozempic cover what is actually available and what it costs. For type 2 diabetes, older tablets such as glimepiride still have a role, especially where cost is the barrier.

Why “Reta” Is Sold Online, and Why to Avoid It

Type “retatrutide India” into a search engine and the first results are often sellers, not regulators. Demand has run ahead of approval, and websites now sell vials labelled “reta”, “reta peptide” or “retatrutide injection”, often marked “for research use”. These products have not passed any CDSCO quality check. There is no guarantee of what is in the vial, at what strength, or whether it was kept cold during shipping, which matters for peptide drugs.

There is a second risk. In trials, the dose is started at 2 mg and raised every four weeks under a doctor’s watch to limit nausea and vomiting. Buying a vial removes that safety net.

What to Do if You Need Treatment Now

If you need treatment for obesity or type 2 diabetes today, discuss the approved options with your doctor rather than waiting for an investigational drug or sourcing one yourself. No approval date exists for India, so waiting is not a treatment plan. A doctor can check your blood sugar and kidney function, then match you to what fits now. Our blood sugar chart by age helps you understand your readings before that visit.

Type 2 diabetes now often starts young, as our guide to type 2 diabetes in young Indians shows. Whether retatrutide becomes an option later depends on approval, final safety data and your own health.

Frequently Asked Questions

References

1. Eli Lilly and Company. TRIUMPH-1 Phase 3 topline results, 21 May 2026.
2. Eli Lilly and Company. TRIUMPH-2 and TRIUMPH-3 topline results and planned FDA submission, 23 July 2026.
3. Eli Lilly and Company. TRIUMPH-2 detailed results, 29 September 2026.
4. Eli Lilly and Company. Second-quarter 2026 results, Form 8-K (retatrutide BLA planned for Q1 2027), 5 August 2026.
5. Reuters. Eli Lilly to offer early access to next-gen obesity drug to some patients, 3 August 2026.
6. The Pharmaceutical Journal. Phase III retatrutide study demonstrates 30% weight loss (with TRIUMPH-4 and TRANSCEND-T2D-1 figures), 2026.
7. ClinicalTrials.gov. TRANSCEND-T2D-1: retatrutide in type 2 diabetes (NCT06354660).
8. Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a Phase 2 trial. N Engl J Med, 2023.